madman
Super Moderator
* Pearlman and Riester discuss why treatment timing remains an important consideration for many men with ED and how rapid absorption through the nasal mucosa could support a more spontaneous sexual experience.
* T-max median of 10 minutes
In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Tom Riester, US general manager of LTR Pharma, at the 2026 American Urological Association Annual Meeting in Washington, DC, to discuss the development of SPONTAN, an investigational intranasal phosphodiesterase type 5 (PDE5) inhibitor designed to treat men with erectile dysfunction (ED). Riester explains how the therapy’s novel delivery mechanism may offer a faster onset of action than currently available oral therapies,1 potentially reducing the planning and anxiety often associated with ED treatment. The conversation also explores LTR Pharma’s regulatory strategy, including its progression through the FDA’s 505(b)(2) pathway and efforts to generate real-world evidence through clinical use in Australia.
Pearlman and Riester discuss why treatment timing remains an important consideration for many men with ED and how rapid absorption through the nasal mucosa could support a more spontaneous sexual experience. Beyond the pharmacologic innovation, the discussion examines broader trends in men’s health, including the increasing prevalence of ED among younger men and the growing emphasis on preventive care, longevity, and sexual wellness across the lifespan. Riester highlights the company’s efforts to evaluate the therapy in diverse patient populations, including men older than 65 years, an age group that has historically been underrepresented in portions of the ED literature.
The conversation concludes with a discussion of prostate cancer survivorship and the importance of addressing sexual health as a component of comprehensive patient care. Riester shares encouraging early observations from Australia in difficult-to-treat populations, including men experiencing ED following prostate cancer treatment. Together, Pearlman and Riester emphasize that improving access to effective sexual health therapies may not only enhance quality of life but also encourage men to engage with the health care system earlier and more consistently. As men's health continues to gain attention across the urologic community, this episode highlights the intersection of innovation, patient-centered care, and the evolving landscape of ED management.
* T-max median of 10 minutes
In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Tom Riester, US general manager of LTR Pharma, at the 2026 American Urological Association Annual Meeting in Washington, DC, to discuss the development of SPONTAN, an investigational intranasal phosphodiesterase type 5 (PDE5) inhibitor designed to treat men with erectile dysfunction (ED). Riester explains how the therapy’s novel delivery mechanism may offer a faster onset of action than currently available oral therapies,1 potentially reducing the planning and anxiety often associated with ED treatment. The conversation also explores LTR Pharma’s regulatory strategy, including its progression through the FDA’s 505(b)(2) pathway and efforts to generate real-world evidence through clinical use in Australia.
Pearlman and Riester discuss why treatment timing remains an important consideration for many men with ED and how rapid absorption through the nasal mucosa could support a more spontaneous sexual experience. Beyond the pharmacologic innovation, the discussion examines broader trends in men’s health, including the increasing prevalence of ED among younger men and the growing emphasis on preventive care, longevity, and sexual wellness across the lifespan. Riester highlights the company’s efforts to evaluate the therapy in diverse patient populations, including men older than 65 years, an age group that has historically been underrepresented in portions of the ED literature.
The conversation concludes with a discussion of prostate cancer survivorship and the importance of addressing sexual health as a component of comprehensive patient care. Riester shares encouraging early observations from Australia in difficult-to-treat populations, including men experiencing ED following prostate cancer treatment. Together, Pearlman and Riester emphasize that improving access to effective sexual health therapies may not only enhance quality of life but also encourage men to engage with the health care system earlier and more consistently. As men's health continues to gain attention across the urologic community, this episode highlights the intersection of innovation, patient-centered care, and the evolving landscape of ED management.
